Stay updated with breaking news from Arix Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deal expands anti-infectives pipeline with addition of novel antifungal Phase 2 candidate, Fosmanogepix Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease ... | April 28, 2021
Opportunity to advance Pfizer’s expertise and deep heritage in infectious disease NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worldwide each ...
About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com Pfizer Acquires Amplyx Pharmaceuticals Opportunity to advance Pfizer's exper...
Arix Bioscience's portfolio firm Amplyx snapped up by Pfizer Amplyx, which develops therapies for debilitating and life-threatening diseases that affect people with compromised immune systems, will be acquired by Pfizer following an initial investment from the pharma giant in 2019 Arix Bioscience PLC (LON:ARIX) said one of its portfolio companies, Amplyx Pharmaceuticals, is to be acquired by US pharma giant Pfizer Inc (NYSE:PFE) in a deal it said will result in a small increase to its holding in the firm. Amplyx, which develops therapies for debilitating and life-threatening diseases that aff...
LogicBio announces clinical and corporate updates DJ LogicBio announces clinical and corporate updates Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Arix Bioscience plc LogicBio announces clinical and corporate updates - First patient in Phase I/II SUNRISE trial expected...